[1]岑璐岚,陈艳红,周坤林,等.基于PICO对ICTRP注册的新型冠状病毒肺炎临床试验分析[J].西部中医药,2022,35(08):11-14.[doi:10.12174/j.issn.2096-9600.2022.08.03]
 CEN Lulan,CHEN Yanhong,ZHOU Kunlin,et al.ICTRP - registered COVID-19 Clinical Trials Based on PICO[J].Western Journal of Traditional Chinese Medicine,2022,35(08):11-14.[doi:10.12174/j.issn.2096-9600.2022.08.03]
点击复制

基于PICO对ICTRP注册的新型冠状病毒肺炎临床试验分析
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
35
期数:
2022年08期
页码:
11-14
栏目:
新冠肺炎
出版日期:
2022-08-15

文章信息/Info

Title:
ICTRP - registered COVID-19 Clinical Trials Based on PICO
作者:
岑璐岚 陈艳红 周坤林 陈俊君 张荣欣 姜枫
广西中医药大学附属瑞康医院,广西 南宁 530011
Author(s):
CEN Lulan CHEN Yanhong ZHOU Kunlin CHEN Junjun ZHANG Rongxin JIANG Feng
Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China
关键词:
新型冠状病毒肺炎国际临床试验注册平台临床试验PICO模式项目分析
Keywords:
COVID-19ICTRPclinical trialsPICO modelproject analysis
分类号:
R563.1
DOI:
10.12174/j.issn.2096-9600.2022.08.03
摘要:
目的分析和总结关于新型冠状病毒肺炎(Corona Virus Disease 2019,COVID-19)的临床试验在国际临床试验注册平台(international clinical trials registry platform,ICTRP)上的注册情况,为COVID-19的临床试验开展及防治提供参考。 方法检索2020年1月1日至2020年3月20日在ICTRP注册中心注册的关于COVID-19的临床试验。基于PICO模式采集、分析信息,对试验的申报单位、研究现场、研究类型等进行分析总结。 结果共检索到522项临床试验。申报单位和研究现场均集中在湖北等疫情严重地区和广东、浙江等经济发达和科研实力较强的地区,其中湖北注册数量和研究现场排名第一。522项临床试验以干预性试验为主。按学科分布把522个试验分3类:西医类试验占68%(356/522),中西医结合类占25%(132/522),心理+行为干预类占7%(34/522)。 结论我国医学家的临床研究意识和能力都得到了很大的提升,但仍存在地区分布差距大、中医药类临床试验较少等问题,需要进一步规范并提高。
Abstract:
ObjectiveTo analyze and summarize the registration status of COVID-19 on ICTRP, so as to provide the reference for the launch of clinical trials for COVID-19, as well as its prevention and treatment. MethodsClinical trials on COVID-19 were retrieved from January 1st, 2020 to March 20th, 2020 in ICTRP registry. After gathering and analyzing the information based on PICO model, the applicants, research site and research type of the trials were analyzed and concluded. ResultsAll 522 clinical trials have been searched. The applicants and research sites are concentrated in severely affected areas such as Hubei province and economically developed and strong scientific research areas such as Guangdong and Zhejiang province, among which, the number of registrations and research sites in Hubei ranked first. Intervention tests were predominant among the 522 clinical trials. All 522 clinical trials could be classified into three types according to subject distribution:the trials of Western medicine, 68% (356/522), the ones of integrated Chinese and Western medicine, 25%(132/522), as well as psychology+behavior intervention type, 7% (34/522). ConclusionThe doctors′ awareness and capacity of clinical research in China have been greatly improved, but there are still some problems such as large regional distribution gap and few TCM clinical trials, which need to be further standardized and improved.

相似文献/References:

[1]李赟,王彩弟,王建云,等.简约远程中医诊疗在新型冠状病毒肺炎隔离病区中的应用[J].西部中医药,2020,33(S1):1.
 LI Yun,WANG Caidi,WANG Jianyun,et al.The Application of Simple Remote TCM Diagnosis and Treatment to COVID-19 Quarantined Inpatient Area[J].Western Journal of Traditional Chinese Medicine,2020,33(08):1.
[2]宋忠阳,雍文兴,张利英,等.新型冠状病毒肺炎的中医临床特征与辨证论治——甘肃经验*[J].西部中医药,2020,33(S1):3.
 SONG Zhongyang,YONG Wenxing,ZHANG Liying,et al.The Experience of TCM Clinical Characteristics, Syndrome Differentiation and Treatment for COVID-19 in Gansu Province[J].Western Journal of Traditional Chinese Medicine,2020,33(08):3.
[3]杜洪霖,马战平△.西北地区新型冠状病毒肺炎的中医特点及防治*[J].西部中医药,2020,33(S1):5.
 DU Honglin,MA Zhanping.TCM Characteristics, the Prevention and Treatment of COVID-19 in Northwest China[J].Western Journal of Traditional Chinese Medicine,2020,33(08):5.
[4]潘文,李盛华,王晓萍,等.中医对新型冠状病毒肺炎的认识与防治探讨[J].西部中医药,2020,33(S1):7.
 PAN Wen,LI Shenghua,WANG Xiaoping,et al.On TCM Understanding, the Prevention and Treatment of COVID-19[J].Western Journal of Traditional Chinese Medicine,2020,33(08):7.
[5]杨海侠,张银萍△,杨长虹,等.新型冠状病毒肺炎疑似患者留观隔离期的护理体会[J].西部中医药,2020,33(S1):13.
[6]丁潇,邹忆怀△,辛大永,等.北京顺义地区新型冠状病毒肺炎的中医临床证候与CT表现[J].西部中医药,2020,33(S1):16.
 DING Xiao,ZOU Yihuai,XIN Dayong,et al.TCM Clinical Syndromes and CT Manifestations of COVID-19 in Shunyi District of Beijing[J].Western Journal of Traditional Chinese Medicine,2020,33(08):16.
[7]桑天庆,周红光△.中医药在新型冠状病毒肺炎疫情中的应用[J].西部中医药,2020,33(S1):18.
 SANG Tianqing,ZHOU Hongguang.TCM Applied to Epidemic Situation of COVID-19[J].Western Journal of Traditional Chinese Medicine,2020,33(08):18.
[8]闫向勇,李 俊,燕忠生△.武汉地区新型冠状病毒肺炎中医证候及病机特点[J].西部中医药,2020,33(S1):20.
 YAN Xiangyong,LI Jun,YAN Zhongsheng.On the Characteristics of TCM Patterns and the Pathogenesis of COVID-19 in Wuhan Region[J].Western Journal of Traditional Chinese Medicine,2020,33(08):20.
[9]曾建峰,李乐愚,缪灿铭,等.岭南道地药材在中山地区新型冠状病毒肺炎防治中的应用*[J].西部中医药,2020,33(S1):24.[doi:10.1056/NEJMoa-2001017]
 and Treatment of COVID-9 in Zhongshan Region.The Application of Lingnan Genuine Drugs to the Prevention[J].Western Journal of Traditional Chinese Medicine,2020,33(08):24.[doi:10.1056/NEJMoa-2001017]
[10]朱玉,黎玉婷,姚德蛟△.从中西医不同角度分析麻杏石甘汤治疗新型冠状病毒肺炎的作用[J].西部中医药,2020,33(S1):26.
 of Traditional Chinese Medicine and Western Medicine.The Functions of Maxing Shigan Tang in the Treatment for COVID-19 from the Angles[J].Western Journal of Traditional Chinese Medicine,2020,33(08):26.

备注/Memo

备注/Memo:
岑璐岚(1994—),女,硕士学位,医师。研究方向:仲景方药的临床应用。全国中医药创新骨干人才培训项目(国中医药办人教函〔2019〕91号);广西第二批广西医学高层次骨于人才培养“139”计划项目(桂卫科教发〔2018〕22号);广西中医药大学附属瑞康医院中医名医工程项目(院字〔2019〕41号)。
更新日期/Last Update: 2022-08-15